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introduction: Danger-associated molecular patterns (DAMPs) can elicit immune 
responses and may subsequently induce an immune-suppressed state. Previous work 
showed that increased plasma levels of DAMPs are associated with immune suppres-
sion and increased susceptibility toward infections in trauma patients. Like trauma, major 
surgical procedures, such as cytoreductive surgery (CRS) combined with hyperthermic 
intraperitoneal chemotherapy (HIPEC), are also thought to cause profound DAMP 
release. Furthermore, the incidence of postoperative infections in these patients, ranging 
from 10 to 36%, is very high compared to that observed in patients undergoing other 
major surgical procedures. We hypothesized that the double hit of surgical trauma (CRS) 
in combination with HIPEC causes excessive DAMP release, which in turn contributes 
to the development of immune suppression. To investigate this, we assessed DAMP 
release in patients undergoing CRS-HIPEC, and investigated its relationship with immune 
suppression and postoperative infections.
Methods: In 20 patients undergoing CRS-HIPEC, blood was obtained at five time 
points: just before surgery (baseline), after CRS, after HIPEC, at ICU admission, and 
1 day after surgery. Circulating levels of DAMPs [heat shock protein (HSP)70, high mobil-
ity group box (HMGB)1, S100A12, S100A8/S100A9, nuclear (n)DNA, mitochondrial (mt)
DNA, lactate dehydrogenase (LDH), a marker of unscheduled cell death], and cytokines 
[tumor necrosis factor (TNF)α, IL-6, IL-8, IL-10, macrophage inflammatory protein 
(MIP)-1α, MIP-1β, and MCP-1] were measured. The extent of immune suppression was 
determined by measuring HLA-DR gene expression and ex vivo leukocytic cytokine 
production capacity.
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results: Plasma levels of DAMPs (maximum fold increases of HSP70: 2.1 [1.5–2.8], 
HMGB1: 5.9 [3.2–9.8], S100A8/S100A9: 3.6 [1.8–5.6], S100A12: 2.6 [1.8–4.3], nDNA 
3.9 [1.0–10.8], LDH 1.7 [1.2–2.5]), and all measured cytokines increased profoundly 
following CRS-HIPEC. Evidence of immune suppression was already apparent during 
the procedure, illustrated by a decrease of HLA-DR expression compared with baseline 
(0.5-fold [0.3–0.9]) and diminished ex vivo pro-inflammatory cytokine production capac-
ity. The increase in HMGB1 levels correlated with the decrease in HLA-DR expression 
(r = −0.46, p = 0.04), and peak HMGB1 concentrations were significantly higher in the 
five patients who went on to develop a postoperative infection (p = 0.04).
conclusion: CRS-HIPEC is associated with profound DAMP release and immune sup-
pression, and plasma HMGB1 levels are related with the occurrence of postoperative 
infections in these patients.
Keywords: danger-associated molecular patterns, high mobility group box 1, immune suppression, hla-Dr, 
postoperative infections, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy
inTrODUcTiOn
Peritoneal carcinomatosis (PC), as a result of dissemination of 
gastrointestinal or gynecological cancer into the peritoneal cavity, 
was formerly regarded as an uncurable condition. However, recent 
advances in our understanding of the pathophysiology of tumor 
spread indicate that PC is a loco-regional disease admissible for 
curative treatment (1). Cytoreductive surgery (CRS) combined 
with hyperthermic intraperitoneal chemotherapy (HIPEC) 
is now advocated as an effective strategy in patients with the 
peritoneum as the only site of dissemination (2). In this selected 
group of patients, CRS-HIPEC results in improved survival for 
both colorectal (3–5) and ovarian malignancies (6, 7) when com-
pared to conventional chemotherapy. Nonetheless, CRS-HIPEC 
remains a complex and challenging procedure, associated with 
postoperative hemodynamic instability, coagulopathy, and meta-
bolic alterations (8, 9). Therefore, the observed survival benefits 
come at the cost of high postoperative morbidity, with reported 
treatment-related complication rates of 23–44% for colorectal (5), 
and 31% for ovarian cancer (7). The most prevalent complication 
is postoperative infection, and strikingly, its incidence (10–36%) 
is very high compared with that observed in patients undergoing 
other major (abdominal) surgical procedures (8, 10–12).
In a large cohort of trauma patients, we have recently dem-
onstrated that release of danger-associated molecular patterns 
(DAMPs) is associated with the development of immunosuppres-
sion and increased susceptibility toward nosocomial infections 
(13). When DAMPs are released upon cellular stress/damage they 
can bind to pattern recognition receptors on antigen presenting 
cells (14), and thereby elicit pro-inflammatory responses and 
a subsequent state of immune suppression (15). This DAMP-
induced immunosuppression captures many hallmarks of sepsis-
induced immunosuppression, and may increase susceptibility 
toward infections (16, 17).
Like trauma, major surgical procedures and chemotherapy are 
thought to cause profound cellular stress and consequent DAMP 
release (18, 19). This led us to hypothesize that the CRS-HIPEC 
procedure, comprising a double hit of surgical trauma and 
hyperthermic chemotherapy, causes excessive DAMP release, 
which in turn contributes to a systemic inflammatory response 
and the development of immune suppression (20). This would 
provide an explanation for the observed high susceptibility 
toward postoperative infections. The aim of this study was to 
investigate DAMP release in patients undergoing CRS-HIPEC 
and elucidate its relationship with the development of immune 
suppression and postoperative infections.
MaTerials anD MeThODs
study Population
Between April 2016 and September 2017, 20 adult patients 
undergoing a CRS-HIPEC procedure at the Radboud University 
Medical Center (Radboudumc) were included in this prospec-
tive observational study. Patients were diagnosed with peritoneal 
metastasis due to a primary colorectal or ovarian malignancy. 
Exclusion criteria were the use of steroids (all dosages) or other 
immunomodulatory medication (e.g., after organ transplant) 
prior to or during the study period. The study was carried out in 
accordance with the recommendations and approved by the local 
ethical committee (CMO Arnhem-Nijmegen; no. 2017-3607) 
with written informed consent from all subjects. Control sam-
ples were obtained from healthy male volunteers (median age 22 
[21–24] years) participating in two human endotoxemia studies 
(12 subjects participating in NCT01835457 (21) and 30 subjects 
participating in NCT02922673), which were also approved by the 
local ethics committee (CMO Arnhem-Nijmegen; no’s. 2012-455 
and 2016-2550). All healthy volunteers provided written informed 
consent and samples were obtained prior to any interventions. All 
study procedures were conducted in accordance with the declara-
tion of Helsinki, including current revisions, and Good Clinical 
Practice guidelines.
crs-hiPec Procedure
All patients underwent a CRS-HIPEC procedure at the 
Radboudumc according to the Radboudumc protocols, and 
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performed by an experienced team. The anesthesia protocol was 
standardized and consisted of general anesthesia in combina-
tion with an epidural catheter. All patients received antibiotic 
prophylaxis (ceftriaxon 2 g i.v. on the evening before surgery and 
metronidazol 500 mg i.v. 60 min before surgery, of which the lat-
ter was repeated when the total length of surgery exceeded 8 h). 
After complete CRS, all subjects underwent a HIPEC procedure, 
consisting of intraperitoneal circulation of oxaliplatin (total dose 
of 460 mg/m2 in dextrose 5% solution during 30 min, 42–43°C) 
preceded by intravenous administration of 5-fluorouracil (total 
dose 400  mg/m2 in 1  h) and leucovorin (total dose 20  mg/m2 
in 30 min). Following surgery, all patients were admitted to the 
intensive care unit (ICU). Postoperative analgesia comprised 
a combination of S-ketamine i.v. (0–10  mg/h) and Patient-
Controlled Epidural Anesthesia (PCEA, with ropivacaine and/or 
sufentanil (max 12 ml/h) for up to 5 days). To prevent postopera-
tive nausea and vomiting, patients received ondansetron (3 times 
daily 4 mg) and metoclopramide (3 times daily 10 mg if needed). 
During ICU stay, selective digestive tract decontamination was 
administered to all patients as part of the standard Radboudumc 
ICU protocol (22). None of the patients was treated with anti-
inflammatory drugs or steroids during the study period.
sample collection
Blood was obtained from the arterial cannula at five time points; 
directly after anesthetic induction (baseline), after CRS, after 
the HIPEC procedure, at ICU admission, and 24 h after start of 
surgery. Ethylenediaminetetraacetic acid (EDTA) anticoagulated 
blood was centrifuged immediately after withdrawal at 1,600 × g 
at 4°C for 10  min, after which plasma was stored at −80°C 
until analysis of heat shock protein (HSP)70, S100A8/S100A9, 
S100A12, and cytokine levels. To determine plasma levels of high 
mobility group box (HMGB)1, lactate dehydrogenase (LDH), 
nuclear (n)DNA, and mitochondrial (mt)DNA, EDTA plasma 
was centrifuged again at 16,000 × g at 4°C for 10 min to remove 
potential remaining platelets and cell debris, after which it was 
stored at −80°C until further analysis. The extent of immune 
suppression was determined by measuring cytokine production 
capacity of leukocytes ex vivo stimulated with lipopolysaccharide 
(LPS), and leukocytic HLA-DRA mRNA expression. Blood for 
ex vivo stimulation was collected in lithium heparin (LH) tubes, 
and blood for mRNA analysis was sampled in PAXgene blood 
RNA tubes (Qiagen, Valencia, CA, USA) and stored according to 
the manufacturer’s instructions. Furthermore, demographic data 
and clinical parameters were obtained from electronic patient 
files. Postoperative infections were scored by two independent 
physicians and classified as severe when organ dysfunction was 
present.
Plasma DaMP levels
We measured DAMPs reflecting cellular stress (23), cellular decay 
(24), and hyperthermic stress (25). The plasma concentrations 
of HSP70/HSPA1A and S100A12 (ENRAGE) were deter-
mined batchwise using enzyme-linked immunosorbent assays 
(ELISA) according to the manufacturer’s instructions (R&D 
systems, Minneapolis, MN, USA). Plasma levels of HMGB1 
were determined using the Shino-test ELISA Kit according to the 
manufacturer’s instructions (IBL International GmbH, Hamburg, 
Germany). Concentrations of S100A8/S100A9 (MRP8/MRP14, 
calprotectin) in plasma were determined using a sandwich ELISA 
at the Institute of Immunology, Muenster, Germany, as described 
previously (26). For nDNA and mtDNA measurements, detailed 
methodology can be found elsewhere (13). Briefly, DNA was iso-
lated using the QIAamp DNA Blood Midi Kit (Qiagen, Valencia, 
CA, USA) and qPCR was performed using iQ SYBR Green PCR 
Master Mix (Bio-Rad Laboratories, Hercules, CA, USA) on a 
CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories, 
Hercules, CA, USA). For nDNA detection, primers for GAPDH 
were used: forward 5′-AGCACCCCTGGCCAAGGTCA-3′ and 
reverse 5-CGGCAGGGAGGAGCCAGTCT-3′. For mtDNA 
detection, primers for MT-ND1 were used: forward 5′-GCCCC 
AACGTTGTAGGCCCC-3′ and reverse 5′AGCTAAGGTCG 
GGGCGGTGA-3′. Patient DNA was compared to DNA isolated 
from whole blood obtained from healthy volunteers. Plasma 
levels of nDNA and mtDNA are expressed as fold change relative 
to the mean Ct value in healthy volunteers using the formula 2ΔCt. 
As a general marker of unscheduled cell death, plasma levels of 
LDH were determined by the Laboratory of Clinical Chemistry 
of Radboudumc (Cobas C8000, Roche Diagnostics, Indianapolis, 
IN, USA).
Plasma cytokine concentrations
Concentrations of tumor necrosis factor (TNF)α, interleukin 
(IL)-6, IL-8, IL-10, macrophage inflammatory protein (MIP)-
1α, MIP-1β, and monocyte chemoattractant protein (MCP)-1 
were determined batchwise using a simultaneous luminex assay 
(Milliplex, Millipore, Billerica, MA, USA) according to the manu-
facturer’s instructions.
Ex Vivo cytokine Production
Leukocyte cytokine production capacity was determined by 
challenging 0.5 mL LH-anticoagulated whole blood with 10 ng/
mL LPS ex vivo at 37°C for 24  h using an in-house developed 
system with prefilled tubes described in detail elsewhere (27). 
Concentrations of TNFα, IL-6, and IL-10 in supernatants of 
stimulated cultures were determined batchwise using ELISA’s 
according to the manufacturer’s instructions (R&D systems, 
Minneapolis, MN, USA) and corrected for blood monocyte 
count determined by the Laboratory of Clinical Chemistry of the 
Radboudumc (Sysmex XE-5000, Sysmex Nederland B.V., Etten-
Leur, The Netherlands).
hla-Dr expression
HLA-DR expression was determined as previously reported 
(13). Briefly, RNA was isolated using the Paxgene Blood RNA kit 
(Qiagen, Valencia, CA, USA) and transcribed into cDNA using 
the iScript cDNA Synthesis kit (Bio-rad, Hercules, CA, USA). 
qPCR analysis was performed using TaqMan gene expression 
assays (Life Technologies, Paisley, UK) for the reference gene 
peptidylpropylisomerase B (PPIB) (#Hs00168719_m1) and 
HLA-DRA (#Hs00219575_m1) on a CFX96 Real-Time PCR 
Detection System (Bio-Rad, Hercules, CA, USA). The HLA-DRA 
gene was used because it was shown to correlate well with flow 
cytometric analysis of monocytic HLA-DR (28), an established 
Table 1 | Patient characteristics.
all patients (n = 20)
Males 11 (55%)
Age (years) 61 [51–72]
Weight (kg) 78 [68–100]
Length (cm) 174 [168–180]
ECOG performance status 1 [1–1]
ASA classification 2 [2–3]
Length of surgery (min) 374 [244–446]
Peritoneal cancer index 9 [2–14]
Transfusion of blood productsa 7 (35%)
Length of TPN administration (days) 7 [5–9]
Postoperative complicationsb 12 (60%)
Grade I 1 (5%)
Grade II 8 (40%)
Grade III 1 (5%)
Grade IV 2 (10%)
Postoperative infections 5 (25%)
ICU length of stay (days) 1.5 [1–2]
Hospital length of stay (days) 11 [8–12]
28-day survival 20 (100%)
Data are presented as median [IQR] or number (percentage).
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ASA, American Society of 
Anesthesiologists; TPN, total parenteral nutrition; ICU, intensive care unit.
aAdministration of erythrocytes or fresh frozen plasma within 24 h after start surgery.
bAccording the Clavien–Dindo classification, the administration of TPN is not taken into 
account as all patients received TPN.
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marker of immune suppression. HLA-DRA expression levels are 
expressed as fold change relative to the expression of PPIB in the 
same sample using the formula 2ΔCt.
statistical analysis
All data were not normally distributed (according to the Shapiro–
Wilk test) and are, therefore, presented as median [interquartile 
range]. Differences between baseline patient data and healthy 
controls, and between patients with and without postoperative 
infections were analyzed using Mann–Whitney U-tests, and dif-
ferences over time within patients were analyzed using Friedman 
tests with Dunn’s post hoc tests. The correlations between different 
DAMPs as well as between DAMPs and cytokines were calculated 
using the method for repeated observations described by Bland 
and Altman (29). Spearman’s correlation coefficients were calcu-
lated for baseline-corrected peak/nadir values. Statistical analyses 
were performed using Graphpad Prism version 5.03 (Graphpad 
Software, La Jolla, CA, USA) and SPSS Statistics version 22 (IBM 
Corporation, Armonk, NY, USA). A p-value of less than 0.05 was 
considered statistically significant.
resUlTs
Patient characteristics
Patient characteristics are listed in Table 1. The majority of the 
patients were treated for peritoneal metastasis following a pri-
mary colon carcinoma (n = 18), and two patients were referred 
after peritoneal metastasis of a primary ovarian carcinoma. Mean 
procedural times were 249 [130–319] minutes for the CRS, 53 
[42–74] minutes for the HIPEC, and 137 [108–170] minutes 
between the end of HIPEC and ICU admission. A complete 
macroscopic cytoreduction was achieved in all patients.
Plasma DaMP and lDh concentrations
HSP70, HMGB1, S100A12, and LDH levels in HIPEC patients at 
baseline did not differ from values obtained in healthy controls. 
S100A8/S100A9 and nDNA levels at baseline were significantly 
higher, whereas mtDNA concentrations were significantly lower 
in patients (Figure 1). Plasma levels of HSP70, HMGB1, S100A8/
S100A9, S100A12, nDNA, and LDH increased during the proce-
dure, whereas mtDNA showed a trend toward increased levels. 
HMGB1 concentrations peaked directly after CRS, whereas 
levels of HSP70, S100A8/S100A9, S100A12, and LDH peaked 
at ICU admission. HSP70 and HMGB1 returned to baseline 
1  day after the procedure, whereas S100A8/S100A9, S100A12, 
nDNA, and LDH concentrations remained elevated for the dura-
tion of the study. HMGB1 correlated with HSP70 and S100A12 
(Figures 2A,B). Furthermore, both S100 proteins and both DNA’s 
were intercorrelated (Figures 2C,D).
Plasma cytokine levels
Baseline plasma cytokine levels in the HIPEC patients were 
similar to those observed in healthy controls, except for slightly 
elevated values of MCP-1 and MIP-1α (Figure  3). Upon the 
CRS-HIPEC procedure, all cytokine levels significantly increased 
compared with baseline, with peak levels observed at ICU admis-
sion. Levels of TNFα, MIP-1α, MIP-1β, and MCP-1 returned to 
baseline 1 day after the procedure. At this time point, concentra-
tions of IL-6, IL-8, and IL-10 were also decreased compared with 
their peak levels, but remained elevated compared to baseline. 
Except for mtDNA, all DAMPs and LDH correlated significantly 
with TNFα, the interleukins, and MCP-1, but only HSP70 and 
HMGB1 correlated with MIP-1α and MIP-1β (Table 2).
immune suppression
At baseline, leukocytic HLA-DR expression was similar between 
HIPEC patients and healthy controls (Figure  4A). During 
the procedure, HLA-DR expression decreased with the lowest 
expression observed directly after the HIPEC procedure. Baseline 
production of TNFα and IL-6 by leukocytes ex vivo stimulated 
with LPS was lower in patients compared with healthy controls, 
whereas ex vivo IL-10 production was not significantly different 
(Figures  4B–D). During and after the CRS-HIPEC procedure, 
ex vivo production capacity was impaired for all cytokines. This 
effect was most pronounced for the pro-inflammatory cytokines 
TNFα and IL-6. The increase in HMGB1 levels (peak-baseline) 
correlated with the decrease in HLA-DR expression (r = −0.46, 
p = 0.04, Figure 4E). No significant correlations between other 
DAMPs and HLA-DR expression were observed.
Postoperative infections
Five (25%) HIPEC patients developed one or more severe post-
operative infections during the follow up period, with a median 
time of 7 [6–9] days between surgery and development of the 
infection. Two patients developed two infections. Primary foci 
were central line-related bloodstream infection (n = 3), pneumo-
nia (n = 2), and abdominal infection (n = 2). All three patients 
developing a central line received TPV at the time of infection. A 
diaphragmatic resection was performed in three cases. In one of 
FigUre 1 | Plasma concentrations of danger-associated molecular patterns and lactate dehydrogenase (LDH). Plasma levels of (a) heat shock protein (HSP)70,  
(b) high mobility group box (HMGB)1, (c) S100A8/S100A9, (D) S100A12, (e) nuclear (n)DNA, (F) mitochondrial (mt)DNA, and (g) LDH in healthy controls (n = 30 
for HSP70, S100A8/S100A9, and S100A12; n = 12 for HMGB1, LDH, nDNA, and mtDNA) and in patients (n = 20) at baseline and at various time points during and 
after the CRS-HIPEC procedure. nDNA and mtDNA levels are depicted as fold change compared to mean levels found in healthy controls. Data are presented as 
median + interquartile range. p-values indicating differences between controls and baseline patient data were calculated using Mann–Whitney U-tests. The p-values 
in each panel indicate differences within patient data over time and were calculated using Friedman tests with Dunn’s post hoc tests (*p < 0.05; **p < 0.01; 
***p < 0.001 compared with baseline). Abbreviations: NS, not significant; CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; ICU, 
intensive care unit; Day +1, first postoperative day.
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these patients, the thoracic cavity was also perfused with oxali-
platin, which was complicated by a pneumonia. Peak HMGB1 
concentrations were significantly higher in patients who went on 
to develop an infection (p = 0.04, Figure 4F). No such relation-
ships were observed for other DAMPs or cytokines.
DiscUssiOn
In this study, we demonstrate that CRS-HIPEC results in DAMP 
release, a systemic inflammatory response, and development of 
an immune-suppressed phenotype, the latter exemplified by a 
FigUre 2 | Correlations between danger-associated molecular patterns. Correlations between (a) high mobility group box (HMGB)1 and heat shock protein 
(HSP)70, (b) HMGB1 and S100A12, (c) S100A8/S100A9 and S100A12, and (D) nuclear (n)DNA and mitochondrial (mt)DNA in CRS-HIPEC patients (n = 20, five 
time points per patient). Correlations were determined using the method for repeated measurements according to Bland and Altman (29).
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decrease in leukocytic HLA-DR expression and diminished ex 
vivo pro-inflammatory cytokine production. This immune sup-
pressive phenotype was already observed immediately following 
CRS, and became more pronounced following HIPEC. Despite 
normalization of inflammatory cytokines in the circulation, 
immune suppression persisted 1 day after surgery. Furthermore, 
HMGB1 levels were related to the occurrence of postoperative 
infections in CRS-HIPEC patients.
Our data show that the CRS-HIPEC procedure results in 
the release of DAMPs and LDH, suggesting noticeable cellular 
damage, (unscheduled) cell death, and/or cellular stress. This 
observation is in accordance with previous studies of our group 
in cohorts of trauma, sepsis, cardiac arrest, and chemotherapy-
treated leukemia patients (13, 19, 30, 31). It is well known that 
virtually all DAMPs are released as a result of cellular rupture 
and/or decay (23, 32, 33). Next to this passive release mechanism, 
several forms of active DAMP release have been described. For 
instance, several proteins of the HSP70 family, representing a 
variety of chaperone proteins residing in the cytoplasm, nucleus, 
extracellular exosomes, and on the cellular membrane (34), 
can be released upon hyperthermic stress (25). S100 proteins, 
implicated in numerous regulatory functions, are released into 
the circulation upon metabolic or oxidative stress (23). Moreover, 
the cytokine-like factor HMGB1 is highly abundant in colorectal 
tumor cells (35), and can be released into the circulation by 
activated immune cells, and by passive leakage from necrotic 
(tumor) cells (36). nDNA and mtDNA, present in all nucleated 
cells, are thought to be largely released upon cell rupture/decay 
(24), although it has been suggested that these can also be actively 
secreted (37). The latter is supported by recent data showing 
increased levels of nDNA in a relatively mild model of systemic 
inflammation in human in vivo (31).
In this study, patients underwent a double hit of surgical trauma 
(CRS) followed by hyperthermic chemotherapy (HIPEC). We 
found increased levels of those DAMPs reflecting cellular decay 
and of LDH (a nonspecific marker of unscheduled cell death) 
directly after CRS, and relatively strong correlations between 
the various DAMPs measured. This suggests that mechanical 
rupture of cells, leading to nonspecific release of various DAMPs, 
likely plays a more important role in the increased DAMP levels 
encountered than the HIPEC procedure. The rapid release of 
HMGB1 after mechanical trauma is in accordance with previous 
work (38–40). Perhaps not surprisingly, plasma levels of HMGB1 
were markedly higher in patients directly after severe mechanical 
trauma (38) and blunted chest trauma (39) compared to the levels 
found in CRS-HIPEC patients in this study, whereas similar levels 
were observed in septic patients (40). Moreover, elevated levels 
of HMGB1 have also been demonstrated in severe burn trauma 
(41). Although oxaliplatin used in the HIPEC procedure exerts 
cytotoxic effects which are mainly caused by inflicting DNA dam-
age (42), and several studies demonstrate release of DAMPs from 
apoptotic chemotherapy-treated cancer cells (43, 44), it is unlikely 
that this contributes to the early DAMP release in our patient 
cohort, as these effects are thought to manifest in a later stage 
FigUre 3 | Plasma concentrations of cytokines. Plasma levels of (a) interleukin (IL)-6, (b) tumor necrosis factor α, (c) IL-8, (D) IL-10, (e) macrophage inflammatory 
protein (MIP)-1α, (F) MIP-1β, and (g) monocyte chemoattractant protein (MCP)-1 in healthy controls (n = 30) and in patients (n = 20) at baseline and at various time 
points during and after the CRS-HIPEC procedure. Data are presented as median + interquartile range. p-values indicating differences between controls and 
baseline patient data were calculated using Mann–Whitney U-tests. The p-values in each panel indicate differences within patient data over time and were calculated 
using Friedman tests with Dunn’s post hoc tests (*p < 0.05; **p < 0.01; ***p < 0.001 compared with baseline). Abbreviations: NS, not significant; CRS, 
cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; ICU, intensive care unit; Day +1, first postoperative day.
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(44). Nevertheless, it is conceivable that chemotherapy-mediated 
apoptosis could contribute to prolonged DAMP release in these 
patients. Interestingly, similar to what was observed in trauma 
and chemotherapy-treated patients (13, 19), but unlike findings 
in patients with septic shock or cardiac arrest (30, 31), mtDNA 
levels did not significantly increase in our patient cohort, and no 
correlations with other DAMPs were present. This suggests that 
other release or clearance mechanisms exist for this DAMP, as has 
been proposed before (30).
Our data reveal that CRS-HIPEC patients display higher levels 
of S100A8/S100A9 at baseline compared to healthy controls. 
This is likely a result of colorectal metastatic disease, as S100A8/
S100A9 is an important mediator in cancer pathology which 
induces growth and stimulates metastasis (45). In accordance 
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with our data, circulating levels of nDNA were also reported to 
be higher in patients with colorectal cancer compared to healthy 
controls (46), and interestingly, nDNA has been proposed as a 
diagnostic and prognostic predictor of colorectal cancer (47).
The suspected interrelation between DAMPs and the inflam-
matory response is supported by our observation that all plasma 
cytokines increased during and following CRS-HIPEC, and 
all DAMPs except for mtDNA correlated well with circulating 
cytokine levels. The absence of a significant increase in mtDNA 
levels likely explains the lack of correlation for this DAMP. As 
such, our data are in line with literature showing that various 
DAMPs can elicit immune responses via ligation of pattern 
recognition receptors. HSP70 is recognized by toll-like receptor 
(TLR)2 and TLR4, ligation of both elicits the release of inflam-
matory cytokines (48). HMGB1 triggers and sustains inflam-
mation and recruits leukocytes by binding to TLRs (49), the 
receptor for advanced glycation endproducts (RAGE), and T-cell 
immunoglobulin and mucin-domain containing (TIM)-3 (50). 
In addition, S100A8/S100A9 binds to a plethora of receptors, 
including TLRs and RAGE, whereas S100A12 specifically binds 
to RAGE (36, 51). Via nuclear factor-kappa B activation, both 
S100 proteins promote production of inflammatory cytokines 
(51). nDNA, next to serving as a general indicator of cellular 
damage, may induce inflammatory responses through ligation of 
retinoid acid-inducible gene-1 and DNA-dependent activator of 
interferon regulatory factors (52).
Patients clearly developed immune suppression during and 
after the CRS-HIPEC procedure, exemplified by a decrease in 
HLA-DR expression, the extent of which was comparable to 
that previously observed in trauma patients (13), and reduced 
production of especially pro-inflammatory cytokines by ex vivo 
stimulated leukocytes. Several studies have demonstrated that 
DAMPs can cause immune suppression or the related phenom-
enon endotoxin tolerance. This has specifically been described for 
HMGB1 (53, 54), HSP70 (55, 56), and S100A8/S100A9 (20, 57, 
58). In addition to DAMP-induced immune dysfunction, recent 
literature shows that immune function can be further suppressed 
by anesthetic drugs, such as ketamine and propofol (59), which 
were used in our study population. Therefore, we cannot rule out 
effects of the anesthetic regime on immune function in this study.
The decrease in HLA-DR expression is a widely known and 
studied hallmark of immune suppression, especially in the sepsis 
field (16). Interestingly, the increase in plasma HMGB1 levels 
was associated with the decrease in HLA-DR expression and, 
importantly, with the development of postoperative infections, 
suggestive of a dominant role for this DAMP. These data are in 
line with previous work in severe blunt chest trauma patients, 
where HMGB1 concentrations were associated with an increased 
risk for sepsis (39). Moreover, in septic shock patients, HMGB1 
levels were significantly lower in the group of patients surviving 
the sepsis episode (40), and peak levels of HMGB1 following gas-
trointestinal surgery correlated with the duration of the systemic 
inflammatory response as well as with postoperative pulmonary 
dysfunction (60).
This study has several shortcomings. First and foremost, due 
to the observational nature of this study, only associations and 
not causative effect can be deduced. Second, our small sample 
FigUre 4 | Markers of immune suppression and postoperative infections. (a) HLA-DR gene expression in leukocytes and production of (b) tumor necrosis factor α, 
(c) interleukin (IL)-6, and (D) IL-10 by leukocytes ex vivo stimulated with lipopolysaccharide in healthy controls (n = 12) and in patients (n = 20) at baseline and at 
various time points during and after the CRS-HIPEC procedure. (e) Correlation between the maximum increase in high mobility group box (HMGB)1 and the 
maximum decrease in HLA-DR expression. (F) Peak HMGB1 plasma levels between patients who went on to develop a postoperative infection and patients who 
did not. HLA-DR levels are depicted as fold change compared to reference gene peptidylpropylisomerase B. Data in panels (a–D) are depicted as 
median + interquartile range. The p-values in panels (a–D) indicating differences between controls and baseline patient in data were calculated using Mann–Whitney 
U-tests. The p-values in panels (a–D) indicate differences within patient data over time and were calculated using Friedman tests with Dunn’s post hoc tests 
(*p < 0.05; **p < 0.01; ***p < 0.001 compared with baseline). Spearman correlation was used in panel (e). The p-value in panel (F) was calculated using the Mann–
Whitney U-test. Abbreviations: NS, not significant; CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; ICU, intensive care unit; Day +1, 
first postoperative day.
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size in combination with a relatively large quantity of measured 
variables does not allow an exploratory factor analysis to identify 
components that discriminate between groups. Third, a larger 
cohort is required to confirm the observed relationship between 
HMGB1 and postoperative infections, and to determine its 
predictive value. Fourth, the follow up period of our study was 
limited to only 1  day. We chose to use such a short follow up 
period because we first wanted to establish whether CRS-HIPEC 
actually resulted in DAMP release and immunological sequelae. 
As such, future studies need to reveal the duration of immune 
suppression and further unravel its relation with postoperative 
infections. Finally, although we hypothesize that CRS is most 
important, we cannot draw definitive conclusions on whether 
CRS or HIPEC is the dominant procedure causing DAMP release 
and immune suppression, because both procedures follow each 
other within a very short time frame. A study including patients, 
where CRS and HIPEC are performed separately with a reason-
able time interval could shed light on this issue. However, this 
approach is rarely used in clinical practice.
cOnclUsiOn
This study demonstrates early DAMP release and immune sup-
pression in patients undergoing CRS-HIPEC. Furthermore, our 
findings of immune suppression at the biochemical level are sup-
ported by the high incidence of serious postoperative infections 
(25%) in our cohort, which is in line with previous data (8, 10–12). 
Interestingly, plasma levels of HMGB1 were related to the occur-
rence of postoperative infections. These data emphasize the need 
to further unravel the mechanisms behind immune dysfunction 
following CRS-HIPEC and similar procedures. If a causative 
relationship between DAMP-induced immune suppression and 
postoperative infections can be established in larger cohorts, it 
could pave the way for future research in the field of immune 
dysfunction following these procedures. Early recognition could 
direct adjunctive immunotherapy to those patients who could 
actually benefit. Similar advances are made in the sepsis field, 
were immunostimulatory agents are being proposed for the 
reversal of immune suppression (61–63). Moreover, therapies 
targeting HMGB1, but also other DAMPs, might be adopted 
from the oncology and sepsis fields (64–66), and applied for use 
in surgery and/or chemotherapy-induced immune suppression.
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